Khapzory is a drug owned by Acrotech Biopharma Inc. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 25, 2039. Details of Khapzory's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11541012 | Compositions comprising disodium levofolinate |
Mar, 2039
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Khapzory's patents.
Latest Legal Activities on Khapzory's Patents
Given below is the list of recent legal activities going on the following patents of Khapzory.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 31 Mar, 2023 | US11541012 |
| Electronic Review Critical | 31 Mar, 2023 | US11541012 |
| Mail O.P. Petition Decision | 31 Mar, 2023 | US11541012 |
| Mail-Petition Decision - Dismissed Critical | 27 Mar, 2023 | US11541012 |
| Petition Decision - Dismissed Critical | 24 Mar, 2023 | US11541012 |
| O.P. Petition Decision | 08 Mar, 2023 | US11541012 |
| Recordation of Patent Grant Mailed Critical | 03 Jan, 2023 | US11541012 |
| Patent Issue Date Used in PTA Calculation Critical | 03 Jan, 2023 | US11541012 |
| Email Notification Critical | 15 Dec, 2022 | US11541012 |
| Issue Notification Mailed Critical | 14 Dec, 2022 | US11541012 |
US patents provide insights into the exclusivity only within the United States, but Khapzory is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Khapzory's family patents as well as insights into ongoing legal events on those patents.
Khapzory's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Khapzory's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 25, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Khapzory Generics:
There are no approved generic versions for Khapzory as of now.
Alternative Brands for Khapzory
There are several other brand drugs using the same active ingredient (Levoleucovorin) as Khapzory. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Acrotech Biopharma |
|
About Khapzory
Khapzory is a drug owned by Acrotech Biopharma Inc. Khapzory uses Levoleucovorin as an active ingredient. Khapzory was launched by Acrotech Biopharma in 2018.
Approval Date:
Khapzory was approved by FDA for market use on 19 October, 2018.
Active Ingredient:
Khapzory uses Levoleucovorin as the active ingredient. Check out other Drugs and Companies using Levoleucovorin ingredient
Dosage:
Khapzory is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 300MG/VIAL | POWDER | Discontinued | INTRAVENOUS |
| 175MG/VIAL | POWDER | Prescription | INTRAVENOUS |